Journals / Retina-Vitreus / 2014 / Cilt: 22 - Sayı: 1

The 24-month results of ıntravitreal ranibizumab treatment in patients with neovascular age-related macular degeneration

Yaş tip yaşa bağlı maküla dejenerasyonu hastalarında intravitreal ranibizumab tedavisinin 24 aylık sonuçları

Pages
21–24
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: The intravitreal ranibizumab with an as needed treatment regimen seems to be effective in the treatment of exuda- tive AMD over 24 months.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: To evaluate the efficacy of intravitreal ranibizumab in exudative age-related macular degeneration (AMD) after a follow-up time of 24 months.
📊
Key Findings & Data:Materials and Methods: The treatment-naive exudative AMD patients who initially received 3 consecutive monthly injec- tions, and then were treated on an as-needed treatment regimen depending on clinical examination and optical coherence tomog- raphy findings were retrospectively evaluated.
💡
Conclusion & Impact:Conclusion: The intravitreal ranibizumab with an as needed treatment regimen seems to be effective in the treatment of exuda- tive AMD over 24 months.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Purpose: To evaluate the efficacy of intravitreal ranibizumab in exudative age-related macular degeneration (AMD) after a follow-up time of 24 months. Materials and Methods: The treatment-naive exudative AMD patients who initially received 3 consecutive monthly injec- tions, and then were treated on an as-needed treatment regimen depending on clinical examination and optical coherence tomog- raphy findings were retrospectively evaluated. The patients were evaluated in regards of best corrected visual acuity (BCVA), central macular thickness (CMT), injection numbers, and complications. Results: A hundred and one eyes of 94 patients were included in the study. The mean age was 73.6±8.2 years (ranging between 53 and 89 years). Forty-five patients (47.9%) were male, and 49 patients (52.1%) were female. The mean pretreatment BCVA, the mean BVCA at month 12, and 24 was 0.90±0.51 LogMAR, 0.73±0.46 LogMAR (p<0.001) and 0.75±0.49 LogMAR (p<0.001), respectively. The mean pretreatment CMT, and the mean CMT at month 12, and month 24 was 331±98 microns, 259±66 microns (p<0.0001) and 262±70 microns (p<0.0001). The mean number of injections at month 12, and 24 was 5.3±1.5, and 8.0±3.0 injec- tions, respectively. Conclusion: The intravitreal ranibizumab with an as needed treatment regimen seems to be effective in the treatment of exuda- tive AMD over 24 months.

Özet

Amaç: Yaş tip yaşa bağlı maküla dejenerasyonu (YBMD) hastalarında gerektiğinde tedavi rejimi ile uygulanan intravitreal ranibizumabın 24 aylık etkinliğinin değerlendirilmesi. Gereç ve Yöntem: Daha önce herhangi bir tedavi almamış; başlangıçta birer ay arayla üç doz intravitreal ranibizumab tedavisi sonrası klinik muayene ve optik koherens tomografi bulgularına göre gerektiğinde yeniden tedavi verilen yaş tip YBMD hastaları geriye dönük olarak incelendi. Hastalar en iyi düzeltilmiş görme keskinliği (EİDGK), merkezi maküla kalınlığı (MMK), enjeksiyon sayısı ve komplikasyonlar açısından değerlendirildi. Bulgular: Doksan dört hastanın 101 gözü çalışmaya alındı. Ortalama yaş 73.6±8.2 (53-89 yaş arası) idi. Kırk beş hasta erkek (%47.9), 49 hasta kadındı (%52.1). Tedavi öncesi, 12. ay ve 24. aydaki ortalama EİDGK sırasıyla; 0.90±0.51 LogMAR, 0.73±0.46 LogMAR (p<0.001) ve 0.75±0.49 LogMAR idi (p<0.001). Tedavi öncesi, 12. ay ve 24. aydaki ortalama MMK sıra- sıyla; 331±98 mikron, 259±66 mikron (p<0.0001) ve 262±70 mikron idi (p<0.0001). On ikinci aydaki ortalama enjeksiyon sayısı 5.3±1.5, 24. aydaki ortalama enjeksiyon sayısı 8.0±3.0 idi. Tartışma: Yaş tip YBMD tedavisinde intravitreal ranibizumab tedavisi gerektiğinde tedavi rejimi ile 24 aya kadar etkin- liğini korumaktadır.

🔖

Cite This Article

ÖZKAYA, A., ALKIN, Z., GARİP, R., YEŞİLKAYA, C., YAZICI, A. T., DEMİROK, A. (2014). The 24-month results of ıntravitreal ranibizumab treatment in patients with neovascular age-related macular degeneration. Retina-Vitreus, Cilt: 22 - Sayı: 1, 21–24. https://ajindex.com/articles/304998

References (14)

  1. Ferris FL 3rd, Fine SL, Hyman L. Age-related macular degenera- tion and blindness due to neovascular maculopathy. Arch Oph- thalmol 1984;102:1640-2
  2. Rasier R, Artunay Ö, Yüzbaşıoğlu E ve ark. Senil maküla dejen- erasyonunun edinsel ve kişisel risk faktörleri ile ilişkisi. Ret-Vit 2007;15:273-5
  3. Chen Y, Bedell M, Zhang K. Age-related macular degeneration: ge- netic and environmental factors of disease. Mol Interv 2010;10:271-1
  4. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesions in age-related macular degen- eration. Results of a randomized clinical trial. Arch Ophthalmol 1991;109:1220-31
  5. Aktaş ZP, Özdek Ş, Gürelik G ve ark. Yaşa bağlı maküla dejen- erasyonuna bağlı gelişen gizli koroidal neovasküler membran tedavisinde transpupiller termoterapi: Uzun dönem sonuçlarımız. Ret-Vit 2006;14:95-100
  6. Özkaya A, Gürcan Z, Yiğit U ve ark. Yaşa bağlı maküla dejen- erasyonu hastalarında fotodinamik tedavi sonuçları. Ret-Vit 2010;18:289-96
  7. Akduman L, Karavellas MP, MacDonald JC, et al. Macular trans- location with retinotomy and retinal rotation for exudative age- related macular degeneration. Retina 1999;19:418-23
  8. Şekeryapan B, Özdek Ş, Özman MC ve ark. Yaşa bağlı maküla de- jenerasyonuna bağlı koroidal neovaskülarizasyon tedavisinde tek başına bevacizumab veya fotodinamik tedavi ile kombinasyon: 12 ay sonuçları. Ret-Vit 2011;19:97-102
  9. Brown DM, Kaiser PK, Michels M, et al. ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related mac- ular degeneration. N Engl J Med 2006;355:1432-44
  10. Rosenfeld PJ, Brown DM, Heier JS, et al. MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-31
  11. Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-re- lated macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol 2009;148:43-58
  12. Schmidt-Erfurth U, Eldem B, Guymer R, et al. EXCITE Study Group. Efficacy and safety of monthly versus quarterly ranibi- zumab treatment in neovascular age-related macular degenera- tion: the EXCITE study. Ophthalmology 2011;118:831-9
  13. Martin DF, Maguire MG, Ying GS, et al. CATT Research Group. Ranibizumab and bevacizumab for neovascular age-related macu- lar degeneration. N Engl J Med 2011;36:1897-908
  14. Brown DM, Michels M, Kaiser PK, et al. ANCHOR Study Group. Ranibizumab versus verteporfin photodynamic therapy for ne